Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $11.1 in the prior trading day, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $11.23, up 1.17%. In other words, the price has increased by $1.17 from its previous closing price. On the day, 0.72 million shares were traded. AUPH stock price reached its highest trading level at $11.243 during the session, while it also had its lowest trading level at $10.915.
Ratios:
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.02. For the most recent quarter (mrq), Quick Ratio is recorded 4.63 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1478199680 and an Enterprise Value of 1244984832. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.26, and their Forward P/E ratio for the next fiscal year is 14.74. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.68 while its Price-to-Book (P/B) ratio in mrq is 4.44. Its current Enterprise Value per Revenue stands at 4.786 whereas that against EBITDA is 15.076.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.30, which has changed by 0.5640669 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $13.54, while it has fallen to a 52-week low of $6.55. The 50-Day Moving Average of the stock is -6.68%, while the 200-Day Moving Average is calculated to be 22.57%.
Shares Statistics:
The stock has traded on average 2.04M shares per day over the past 3-months and 1341810 shares per day over the last 10 days, according to various share statistics. A total of 132.67M shares are outstanding, with a floating share count of 118.93M. Insiders hold about 9.65% of the company’s shares, while institutions hold 43.76% stake in the company. Shares short for AUPH as of 1759190400 were 9164458 with a Short Ratio of 4.48, compared to 1756425600 on 8926139. Therefore, it implies a Short% of Shares Outstanding of 9164458 and a Short% of Float of 7.630000000000001.
Earnings Estimates
. The current rating of Aurinia Pharmaceuticals Inc (AUPH) reflects the combined expertise of 6.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.15, with high estimates of $0.22 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.81 and $0.5 for the fiscal current year, implying an average EPS of $0.65. EPS for the following year is $0.76, with 6.0 analysts recommending between $1.22 and $0.57.
Revenue Estimates
7 analysts predict $67.7M in revenue for . The current quarter. It ranges from a high estimate of $71.1M to a low estimate of $65.03M. As of . The current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $67.77MFor the next quarter, 7 analysts are estimating revenue of $70.27M. There is a high estimate of $72.6M for the next quarter, whereas the lowest estimate is $66.5M.
A total of 7 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $276.2M, while the lowest revenue estimate was $265M, resulting in an average revenue estimate of $270.48M. In the same quarter a year ago, actual revenue was $235.13MBased on 7 analysts’ estimates, the company’s revenue will be $309.2M in the next fiscal year. The high estimate is $356.92M and the low estimate is $284.45M.
